×

We've got news for you.

Register on TimesLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Omicron vaccine is all well and good, but the real money is on an all-in-one jab

Researchers look for alternative strategy as variant-specific vaccines seem doomed to play perpetual catch-up

20 January 2022 - 20:56 By Lisa Jarvis

Pfizer and Moderna are starting to churn out doses of Omicron-specific vaccines, and they say they could have data on whether the shots are effective as soon as March. But is this the best way to build and maintain protection against Covid-19?..

This article is reserved for Sunday Times subscribers.

A subscription gives you full digital access to all Sunday Times content.

Already subscribed? Simply sign in below.

Registered on the BusinessLIVE, Business Day or Financial Mail websites? Sign in with the same details.



Questions or problems? Email helpdesk@timeslive.co.za or call 0860 52 52 00.